Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib + Cetuximab +/- Encorafenib in Unresectable/Metastatic Colorectal Cancer
NCT05985954Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulixertinib in colorectal cancer (CRC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
ulixertinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05985954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985954.